Clinical experience from the first compact IMPT Proton Therapy Center: the advantages of treating in an open gantry environment
26/01/2018
/
Event
/
IMPT
The Willis-Knighton Health System, headquartered in Shreveport, Louisiana, is a not-for-profit community healthcare corporation with four general acute care...
Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.
12/01/2023
/
Publications
/
A retrospective study by the MGH group reported outcomes of 59 adult patients with medulloblastoma treated with proton CSI. Gross total resection was achieved...
Proton beam therapy for skull base chordomas: a systematic review of tumor control rates and survival rates.
12/01/2023
/
Publications
/
Based on the data from 16 studies involving 752 patients, this review reported outcomes of PBT for skull base chordomas. Ninety-five percent of the patients...
Cochlear-optimized treatment planning in photon and proton radiosurgery for vestibular schwannoma patients.
23/11/2023
/
Publications
/
This study compared photon radiosurgery plans and IMPT plans to the clinically delivered photon treatment plans of 24 vestibular schwannoma patients to...
Hypofractionated proton therapy for benign tumors of the central nervous system: A systematic review of the literature.
23/11/2023
/
Publications
/
This systematic review summarized results of the literature in the setting of patients treated with hypofractionated PT for benign lesions of the central...
High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis.
28/02/2024
/
Publications
/
This study compared the survival outcomes and toxicities of high-dose PBT of 96.6 GyRBE and CRT of 60 Gy using propensity score-matched treatment cohorts. From...
Long-term outcomes of fractionated proton beam therapy for benign or radiographic intracranial meningioma.
28/02/2024
/
Publications
/
This study reported outcomes of 59 (64 lesions) patients with benign intracranial meningioma treated with PBT to a median total dose of 50.4 GyRBE at 1.8 GyRBE...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.